• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Fanapt Falls Flat! Link from the Street.com









Got me thinking..... If all the psychotic bastards that are in this fuck-up company were placed on Fanapt by their psychiatrists.....

..... we could DOUBLE our numbers !!!

WOW !

now, that's innovative thinking from a frustrated rep
 
























I am glad he left. As a marketer he was never on the same page as me. He criticized everything I did. He may be better looking than me, but he didnt have the "it" factor which is why I have progressed so much quicker so much younger- Go Big Blue!!!!!
 








Got a call yesterday from a psychiatrist friend who is an early adopter who tx's a significant amount of schiz. Said he really gave Fanapt a fair trial (at least 20 patients) and the outcomes were quite disappointing. Not one patient stayed with it. The main problem was lack of efficacy. I hope those of you promoting it either find other work or make it through the next downsizing.
 




Got a call yesterday from a psychiatrist friend who is an early adopter who tx's a significant amount of schiz. Said he really gave Fanapt a fair trial (at least 20 patients) and the outcomes were quite disappointing. Not one patient stayed with it. The main problem was lack of efficacy. I hope those of you promoting it either find other work or make it through the next downsizing.

This is probably a valid post. In the Vanda trials lack of efficacy was the key issue why Vanda could never get FDA approval. They turned over the data to Novartis who helped them massage it through the FDA. You have to wonder if there were some greased palms along the way!
 
































How is Latuda doing compared to Fanapt?

Latuda is moving because they are promoting it off label. Now, management tells the Fanapt reps to hit every psych regardless of their schizophrenia volume. That is wink, wink, for off label promotion of other indications.

Why risk a massive fine for a product that is never going to take off?